A Patient with Escherichia coli Bacteremia and COVID-19 Co-Infection: A Case Report for the Louisville COVID-19 Epidemiology Study by Moore, Sarah E, PharmD et al.
University of Louisville Journal of Respiratory Infections
CASE REPORT
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/15 1
Abstract
Patients with COVID-19 may have co-infections with other microorganisms. Here we report a 
case of a patient with an E. coli bacteremia secondary to a urinary tract infection, who experi-
enced fevers while on active antimicrobial therapy. The patient was eventually tested for COV-
ID-19 and found to be positive. This case emphasizes the need to suspect COVID-19 even in 
patients with documented bacterial infection. 
Introduction
Current CDC guidance encourages health care providers to consider testing for SARS-
CoV-2 infection in patients with signs and symptoms consistent with COVID infection. 
[1] Reports of both viral and bacterial co-infection are now emerging. [2-6] We describe 
a patient with E. coli bacteremia secondary to a urinary tract infection, who developed 
persistent high fevers despite receiving appropriate antimicrobial therapy based on sus-
ceptibility results. Due to clinical deterioration, the patient was tested for novel corona-
virus infection and found to have a positive nasopharyngeal PCR. Our case report serves 
as a caution against ruling out SARS-CoV-2 when another infectious process may not 
fully explain a patient’s symptoms.   
Case Presentation
A 64-year-old white male presented to the emergency department with a chief complaint 
of burning with urination starting 4 days prior to admission. His past medical history 
was significant for type 2 diabetes mellitus, hypertension and pancreatitis. The patient 
also endorsed urinary retention, gait instability, nausea, vomiting and chills. Blood and 
urine cultures were collected, both of which grew pan-susceptible E. coli. The patient 
received active antibiotics for his E. coli infection throughout his hospitalization. 
On hospital day 2, the patient had a urinary catheter placed due to continued urinary 
retention. He also reported diarrhea and was tested for C. difficile infection, which was 
negative. Repeat blood cultures were obtained and demonstrated no growth, confirming 
clearance of the patient’s bacteremia. 
 
On hospital day 4, a CT of the abdomen/pelvis was obtained, which noted an evolving 
prostate abscess (Figure 1). Of note, the patient also began reporting a dry cough and de-
veloped high fevers with a maximum temperature of 103.4o F. That evening, he required 
BiPAP in order to maintain SaO2 >90%. He was eventually intubated due to respiratory 
failure. At this point, a nasopharyngeal COVID-19 PCR test was obtained due to rapid 
clinical deterioration despite adequate management of the patient’s bacterial infection. 
The patient was also placed into COVID-19 appropriate isolation. 
The patient went on to develop multi-organ failure, including acute respiratory distress 
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syndrome (Figure 2), and required continuous renal replacement therapy and multiple vasopressors to maintain MAP 
>65 mmHg. On hospital day 9, the COVID-19 PCR test resulted positive, confirming COVID-19 coinfection. At this time, 
the patient was non-responsive off sedation and was compassionately extubated shortly thereafter. 
Discussion
SARS-CoV-2 can present with a constellation of non-specific symptoms. In our patient, nausea and diarrhea were pos-
sibly the first COVID-19 related symptoms to present. This was followed by a non-productive cough, fevers, and even-
tual respiratory decompensation. [7,8] Initially, the patient’s fevers while on antibiotics were thought to be attributable 
to his undrained prostate abscess. However, given that this patient was initially afebrile and then developed high fe-
vers while receiving antibiotics, this raised suspicion for a second infectious process. The median incubation period 
of SARS-CoV-2 appears to be about 5 days. Lauer et al reported that in their cohort, <2.5% of patients displayed any 
symptoms within 2.2 days. [9-11] Based on this information, it seems most likely that our patient acquired COVID-19 
prior to presenting to the hospital. 
Guidelines from the Surviving Sepsis Campaign suggest that based on current evidence, the presence of another respi-
ratory pathogen does not necessarily rule out the possibility of COVID-19. [12] In this case, there was delay in clinical 
suspicion and COVID-19 testing. During the first four days of hospitalization, the patient was not in isolation resulting 
in numerous healthcare worker exposures. This highlights the importance of the aforementioned recommendation. 
Universal patient screening upon admission may have identified this patient as a COVID-19 case earlier.
Figure 1. CT abdomen/pelvis obtained on hospital day 2. Findings significant for enlarged prostate (1), 
seminal vesicles and thick-walled urinary bladder (not visualized here). New focal 2 x 1.3 cm region 
of decreased attenuation at the right lateral periphery of the prostate (2). It is unclear if this represents 
phlegmon/early abscess in the setting of prostatitis.
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Figure 2. CT chest obtained on hospital day 5. Findings include extensive bilateral dense consolidation 
involving the upper and lower lobes. There is a small left pleural effusion. Overall appearance is consistent 
with widespread pneumonia and acute respiratory distress syndrome (ARDS).  
Clinical outcomes in patients with COVID-19 and bacterial coinfections have not been well-described. Fan and col-
leagues describe a case of a patient with COVID-19 and M. pneumoniae infection. [3] These authors suggest that failing 
to treat other causes of infection in COVID-19 patients is likely to increase morbidity and mortality. 
Worse outcomes were observed in patients with bacterial coinfection and H1N1 influenza.  These patients were more 
likely to require mechanical ventilation and longer ICU stays than patients without coinfection. [13] Additionally, pa-
tients with bacterial coinfection had an inpatient mortality rate of 31%, versus 21% in patients with influenza alone 
(p=0.002). [13] It is possible that similar outcomes may be observed in the SARS-CoV-2 pandemic, but further data is 
needed before any conclusions may be drawn. 
In conclusion, this case highlights the importance of considering COVID-19 infection even in the setting of a confirmed 
alternate infectious diagnosis. Clinicians should consider isolation and testing for coinfection if clinically appropriate. 
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